IL9 and inflammatory bowel disease: As compared to other cytokines that have model-dependent protective or pathogenic roles in IBD (i.e., IFN-γ and IL-17), IL-9 appears to have a consistent pathogenic role across disease models making it a potential druggable target in IBD.